Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;4(2):147-52.
doi: 10.1007/s13244-013-0220-5. Epub 2013 Feb 9.

ESR statement on the stepwise development of imaging biomarkers

European Society of Radiology (ESR)

ESR statement on the stepwise development of imaging biomarkers

European Society of Radiology (ESR). Insights Imaging. 2013 Apr.

Abstract

Development of imaging biomarkers is a structured process in which new biomarkers are discovered, verified, validated and qualified against biological processes and clinical end-points. The validation process not only concerns the determination of the sensitivity and specificity but also the measurement of reproducibility. Reproducibility assessments and standardisation of the acquisition and data analysis methods are crucial when imaging biomarkers are used in multicentre trials for assessing response to treatment. Quality control in multicentre trials can be performed with the use of imaging phantoms. The cost-effectiveness of imaging biomarkers also needs to be determined. A lot of imaging biomarkers are being developed, but there are still unmet needs-for example, in the detection of tumour invasiveness. Main Messages • Using imaging biomarkers to streamline drug discovery and disease progression is a huge advancement in healthcare. • The qualification and technical validation of imaging biomarkers pose unique challenges in that the accuracy, methods, standardisations and reproducibility are strictly monitored. • The clinical value of new biomarkers is of the highest priority in terms of patient management, assessing risk factors and disease prognosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Steps for the development of imaging biomarkers (adapted from [5])
See this image and copyright information in PMC

References

    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer. 2012;48(4):409–415. doi: 10.1016/j.ejca.2011.11.037. - DOI - PubMed
    1. European Society of Radiology White paper on imaging biomarkers. Insights Imaging. 2010;1(2):42–45. doi: 10.1007/s13244-010-0025-8. - DOI - PMC - PubMed
    1. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81(1):104–107. doi: 10.1038/sj.clpt.6100017. - DOI - PubMed
    1. Marti Bonmati L, Alberich-Bayarri A, Garcia-Marti G, Sanz Requena R, Pérez Castillo C, Carot Sierra JM, Herrera M. Imaging biomarkers, quantitative imaging, and bioengineering. Radiol. 2012;54(3):269–278. doi: 10.1134/S1066362212030095. - DOI - PubMed

LinkOut - more resources